

**E2SSB 5367** - H COMM AMD

By Committee on Regulated Substances & Gaming

1 Strike everything after the enacting clause and insert the  
2 following:

3 "Sec. 1. RCW 15.140.020 and 2022 c 16 s 19 are each amended to  
4 read as follows:

5 The definitions in this section apply throughout this chapter  
6 unless the context clearly requires otherwise.

7 (1) "Agriculture improvement act of 2018" means sections 7605,  
8 10113, 10114, and 12619 of the agriculture improvement act of 2018,  
9 P.L. 115-334.

10 (2) "Cannabis" has the meaning provided in RCW 69.50.101.

11 (3) "Crop" means hemp grown as an agricultural commodity.

12 (4) "Cultivar" means a variation of the plant *Cannabis sativa L.*  
13 that has been developed through cultivation by selective breeding.

14 (5) "Department" means the Washington state department of  
15 agriculture.

16 (6) "Food" has the same meaning as defined in RCW 69.07.010.

17 (7) "Hemp" means the plant *Cannabis sativa L.* and any part of  
18 that plant, including the seeds thereof and all derivatives,  
19 extracts, cannabinoids, isomers, acids, salts, and salts of isomers,  
20 whether growing or not, with a delta-9 tetrahydrocannabinol  
21 concentration of not more than 0.3 percent on a dry weight basis.

22 (8) "Hemp consumable" means a product that is sold or provided to  
23 another person, that is:

24 (a) Made of hemp;

25 (b) Not a cannabis product, as defined in RCW 69.50.101; and

26 (c) Intended to be consumed or absorbed inside the body by any  
27 means, including inhalation, ingestion, or insertion.

28 (9) "Hemp processor" means a person who takes possession of raw  
29 hemp material with the intent to modify, package, or sell a  
30 transitional or finished hemp product.

1 ((+9)) (10) (a) "Industrial hemp" means all parts and varieties  
2 of the genera *Cannabis*, cultivated or possessed by a grower, whether  
3 growing or not, that contain a tetrahydrocannabinol concentration of  
4 0.3 percent or less by dry weight that was grown under the industrial  
5 hemp research program as it existed on December 31, 2019.

6 (b) "Industrial hemp" does not include plants of the genera  
7 *Cannabis* that meet the definition of "cannabis."

8 ((+10)) (11) "Postharvest test" means a test of ((delta-9))  
9 tetrahydrocannabinol concentration levels of hemp after being  
10 harvested based on:

11 (a) Ground whole plant samples without heat applied; or

12 (b) Other approved testing methods.

13 ((+11)) (12) "Process" means the processing, compounding, or  
14 conversion of hemp into hemp commodities or products.

15 ((+12)) (13) "Produce" or "production" means the planting,  
16 cultivation, growing, or harvesting of hemp including hemp seed.

17 **Sec. 2.** RCW 69.50.101 and 2022 c 16 s 51 are each reenacted and  
18 amended to read as follows:

19 The definitions in this section apply throughout this chapter  
20 unless the context clearly requires otherwise.

21 (a) "Administer" means to apply a controlled substance, whether  
22 by injection, inhalation, ingestion, or any other means, directly to  
23 the body of a patient or research subject by:

24 (1) a practitioner authorized to prescribe (or, by the  
25 practitioner's authorized agent); or

26 (2) the patient or research subject at the direction and in the  
27 presence of the practitioner.

28 (b) "Agent" means an authorized person who acts on behalf of or  
29 at the direction of a manufacturer, distributor, or dispenser. It  
30 does not include a common or contract carrier, public  
31 warehouseperson, or employee of the carrier or warehouseperson.

32 (c) "Board" means the Washington state liquor and cannabis board.

33 (d) "Cannabis" means all parts of the plant *Cannabis*, whether  
34 growing or not, with a THC concentration greater than 0.3 percent on  
35 a dry weight basis (~~(; the seeds thereof; the resin extracted from any~~  
36 ~~part of the plant; and every compound, manufacture, salt, derivative,~~  
37 ~~mixture, or preparation of the plant, its seeds or resin. The term~~  
38 ~~does not include:~~

1       ~~(1) The mature stalks of the plant, fiber produced from the~~  
2 ~~stalks, oil or cake made from the seeds of the plant, any other~~  
3 ~~compound, manufacture, salt, derivative, mixture, or preparation of~~  
4 ~~the mature stalks (except the resin extracted therefrom), fiber, oil,~~  
5 ~~or cake, or the sterilized seed of the plant which is incapable of~~  
6 ~~germination; or~~

7       ~~(2) Hemp or industrial hemp as defined in RCW 15.140.020,))~~  
8 during the growing cycle through harvest and usable cannabis.  
9 "Cannabis" does not include hemp or industrial hemp as defined in RCW  
10 15.140.020, or seeds used for licensed hemp production under chapter  
11 15.140 RCW.

12       (e) "Cannabis concentrates" means products consisting wholly or  
13 in part of the resin extracted from any part of the plant *Cannabis*  
14 and having a THC concentration greater than ten percent.

15       (f) "Cannabis processor" means a person licensed by the board to  
16 process cannabis into cannabis concentrates, useable cannabis, and  
17 cannabis-infused products, package and label cannabis concentrates,  
18 useable cannabis, and cannabis-infused products for sale in retail  
19 outlets, and sell cannabis concentrates, useable cannabis, and  
20 cannabis-infused products at wholesale to cannabis retailers.

21       (g) "Cannabis producer" means a person licensed by the board to  
22 produce and sell cannabis at wholesale to cannabis processors and  
23 other cannabis producers.

24       (h) (1) "Cannabis products" means useable cannabis, cannabis  
25 concentrates, and cannabis-infused products as defined in this  
26 section, including any product intended to be consumed or absorbed  
27 inside the body by any means including inhalation, ingestion, or  
28 insertion, with any detectable amount of THC.

29       (2) "Cannabis products" also means any product containing only  
30 THC content.

31       (3) "Cannabis products" does not include cannabis health and  
32 beauty aids as defined in RCW 69.50.575 or products approved by the  
33 United States food and drug administration.

34       (i) "Cannabis researcher" means a person licensed by the board to  
35 produce, process, and possess cannabis for the purposes of conducting  
36 research on cannabis and cannabis-derived drug products.

37       (j) "Cannabis retailer" means a person licensed by the board to  
38 sell cannabis concentrates, useable cannabis, and cannabis-infused  
39 products in a retail outlet.

1 (k) "Cannabis-infused products" means products that contain  
2 cannabis or cannabis extracts, are intended for human use, are  
3 derived from cannabis as defined in subsection (d) of this section,  
4 and have a THC concentration no greater than ten percent. The term  
5 "cannabis-infused products" does not include either useable cannabis  
6 or cannabis concentrates.

7 (l) "CBD concentration" has the meaning provided in RCW  
8 69.51A.010.

9 (m) "CBD product" means any product containing or consisting of  
10 cannabidiol.

11 (n) "Commission" means the pharmacy quality assurance commission.

12 (o) "Controlled substance" means a drug, substance, or immediate  
13 precursor included in Schedules I through V as set forth in federal  
14 or state laws, or federal or commission rules, but does not include  
15 hemp or industrial hemp as defined in RCW 15.140.020.

16 (p)(1) "Controlled substance analog" means a substance the  
17 chemical structure of which is substantially similar to the chemical  
18 structure of a controlled substance in Schedule I or II and:

19 (i) that has a stimulant, depressant, or hallucinogenic effect on  
20 the central nervous system substantially similar to the stimulant,  
21 depressant, or hallucinogenic effect on the central nervous system of  
22 a controlled substance included in Schedule I or II; or

23 (ii) with respect to a particular individual, that the individual  
24 represents or intends to have a stimulant, depressant, or  
25 hallucinogenic effect on the central nervous system substantially  
26 similar to the stimulant, depressant, or hallucinogenic effect on the  
27 central nervous system of a controlled substance included in Schedule  
28 I or II.

29 (2) The term does not include:

30 (i) a controlled substance;

31 (ii) a substance for which there is an approved new drug  
32 application;

33 (iii) a substance with respect to which an exemption is in effect  
34 for investigational use by a particular person under Section 505 of  
35 the federal food, drug, and cosmetic act, 21 U.S.C. Sec. 355, or  
36 chapter 69.77 RCW to the extent conduct with respect to the substance  
37 is pursuant to the exemption; or

38 (iv) any substance to the extent not intended for human  
39 consumption before an exemption takes effect with respect to the  
40 substance.

1 (q) "Deliver" or "delivery" means the actual or constructive  
2 transfer from one person to another of a substance, whether or not  
3 there is an agency relationship.

4 (r) "Department" means the department of health.

5 (s) "Designated provider" has the meaning provided in RCW  
6 69.51A.010.

7 (t) "Dispense" means the interpretation of a prescription or  
8 order for a controlled substance and, pursuant to that prescription  
9 or order, the proper selection, measuring, compounding, labeling, or  
10 packaging necessary to prepare that prescription or order for  
11 delivery.

12 (u) "Dispenser" means a practitioner who dispenses.

13 (v) "Distribute" means to deliver other than by administering or  
14 dispensing a controlled substance.

15 (w) "Distributor" means a person who distributes.

16 (x) "Drug" means (1) a controlled substance recognized as a drug  
17 in the official United States pharmacopoeia/national formulary or the  
18 official homeopathic pharmacopoeia of the United States, or any  
19 supplement to them; (2) controlled substances intended for use in the  
20 diagnosis, cure, mitigation, treatment, or prevention of disease in  
21 individuals or animals; (3) controlled substances (other than food)  
22 intended to affect the structure or any function of the body of  
23 individuals or animals; and (4) controlled substances intended for  
24 use as a component of any article specified in (1), (2), or (3) of  
25 this subsection. The term does not include devices or their  
26 components, parts, or accessories.

27 (y) "Drug enforcement administration" means the drug enforcement  
28 administration in the United States Department of Justice, or its  
29 successor agency.

30 (z) "Electronic communication of prescription information" means  
31 the transmission of a prescription or refill authorization for a drug  
32 of a practitioner using computer systems. The term does not include a  
33 prescription or refill authorization verbally transmitted by  
34 telephone nor a facsimile manually signed by the practitioner.

35 (aa) "Immature plant or clone" means a plant or clone that has no  
36 flowers, is less than twelve inches in height, and is less than  
37 twelve inches in diameter.

38 (bb) "Immediate precursor" means a substance:

1 (1) that the commission has found to be and by rule designates as  
2 being the principal compound commonly used, or produced primarily for  
3 use, in the manufacture of a controlled substance;

4 (2) that is an immediate chemical intermediary used or likely to  
5 be used in the manufacture of a controlled substance; and

6 (3) the control of which is necessary to prevent, curtail, or  
7 limit the manufacture of the controlled substance.

8 (cc) "Isomer" means an optical isomer, but in subsection (gg)(5)  
9 of this section, RCW 69.50.204(a) (12) and (34), and 69.50.206(b)(4),  
10 the term includes any geometrical isomer; in RCW 69.50.204(a) (8) and  
11 (42), and 69.50.210(c) the term includes any positional isomer; and  
12 in RCW 69.50.204(a)(35), 69.50.204(c), and 69.50.208(a) the term  
13 includes any positional or geometric isomer.

14 (dd) "Lot" means a definite quantity of cannabis, cannabis  
15 concentrates, useable cannabis, or cannabis-infused product  
16 identified by a lot number, every portion or package of which is  
17 uniform within recognized tolerances for the factors that appear in  
18 the labeling.

19 (ee) "Lot number" must identify the licensee by business or trade  
20 name and Washington state unified business identifier number, and the  
21 date of harvest or processing for each lot of cannabis, cannabis  
22 concentrates, useable cannabis, or cannabis-infused product.

23 (ff) "Manufacture" means the production, preparation,  
24 propagation, compounding, conversion, or processing of a controlled  
25 substance, either directly or indirectly or by extraction from  
26 substances of natural origin, or independently by means of chemical  
27 synthesis, or by a combination of extraction and chemical synthesis,  
28 and includes any packaging or repackaging of the substance or  
29 labeling or relabeling of its container. The term does not include  
30 the preparation, compounding, packaging, repackaging, labeling, or  
31 relabeling of a controlled substance:

32 (1) by a practitioner as an incident to the practitioner's  
33 administering or dispensing of a controlled substance in the course  
34 of the practitioner's professional practice; or

35 (2) by a practitioner, or by the practitioner's authorized agent  
36 under the practitioner's supervision, for the purpose of, or as an  
37 incident to, research, teaching, or chemical analysis and not for  
38 sale.

39 (gg) "Narcotic drug" means any of the following, whether produced  
40 directly or indirectly by extraction from substances of vegetable

1 origin, or independently by means of chemical synthesis, or by a  
2 combination of extraction and chemical synthesis:

3 (1) Opium, opium derivative, and any derivative of opium or opium  
4 derivative, including their salts, isomers, and salts of isomers,  
5 whenever the existence of the salts, isomers, and salts of isomers is  
6 possible within the specific chemical designation. The term does not  
7 include the isoquinoline alkaloids of opium.

8 (2) Synthetic opiate and any derivative of synthetic opiate,  
9 including their isomers, esters, ethers, salts, and salts of isomers,  
10 esters, and ethers, whenever the existence of the isomers, esters,  
11 ethers, and salts is possible within the specific chemical  
12 designation.

13 (3) Poppy straw and concentrate of poppy straw.

14 (4) Coca leaves, except coca leaves and extracts of coca leaves  
15 from which cocaine, ecgonine, and derivatives or ecgonine or their  
16 salts have been removed.

17 (5) Cocaine, or any salt, isomer, or salt of isomer thereof.

18 (6) Cocaine base.

19 (7) Ecgonine, or any derivative, salt, isomer, or salt of isomer  
20 thereof.

21 (8) Any compound, mixture, or preparation containing any quantity  
22 of any substance referred to in (1) through (7) of this subsection.

23 (hh) "Opiate" means any substance having an addiction-forming or  
24 addiction-sustaining liability similar to morphine or being capable  
25 of conversion into a drug having addiction-forming or addiction-  
26 sustaining liability. The term includes opium, substances derived  
27 from opium (opium derivatives), and synthetic opiates. The term does  
28 not include, unless specifically designated as controlled under RCW  
29 69.50.201, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan  
30 and its salts (dextromethorphan). The term includes the racemic and  
31 levorotatory forms of dextromethorphan.

32 (ii) "Opium poppy" means the plant of the species *Papaver*  
33 *somniferum* L., except its seeds.

34 (jj) "Person" means individual, corporation, business trust,  
35 estate, trust, partnership, association, joint venture, government,  
36 governmental subdivision or agency, or any other legal or commercial  
37 entity.

38 (kk) "Plant" has the meaning provided in RCW 69.51A.010.

39 (ll) "Poppy straw" means all parts, except the seeds, of the  
40 opium poppy, after mowing.

1 (mm) "Practitioner" means:

2 (1) A physician under chapter 18.71 RCW; a physician assistant  
3 under chapter 18.71A RCW; an osteopathic physician and surgeon under  
4 chapter 18.57 RCW; an optometrist licensed under chapter 18.53 RCW  
5 who is certified by the optometry board under RCW 18.53.010 subject  
6 to any limitations in RCW 18.53.010; a dentist under chapter 18.32  
7 RCW; a podiatric physician and surgeon under chapter 18.22 RCW; a  
8 veterinarian under chapter 18.92 RCW; a registered nurse, advanced  
9 registered nurse practitioner, or licensed practical nurse under  
10 chapter 18.79 RCW; a naturopathic physician under chapter 18.36A RCW  
11 who is licensed under RCW 18.36A.030 subject to any limitations in  
12 RCW 18.36A.040; a pharmacist under chapter 18.64 RCW or a scientific  
13 investigator under this chapter, licensed, registered or otherwise  
14 permitted insofar as is consistent with those licensing laws to  
15 distribute, dispense, conduct research with respect to or administer  
16 a controlled substance in the course of their professional practice  
17 or research in this state.

18 (2) A pharmacy, hospital or other institution licensed,  
19 registered, or otherwise permitted to distribute, dispense, conduct  
20 research with respect to or to administer a controlled substance in  
21 the course of professional practice or research in this state.

22 (3) A physician licensed to practice medicine and surgery, a  
23 physician licensed to practice osteopathic medicine and surgery, a  
24 dentist licensed to practice dentistry, a podiatric physician and  
25 surgeon licensed to practice podiatric medicine and surgery, a  
26 licensed physician assistant or a licensed osteopathic physician  
27 assistant specifically approved to prescribe controlled substances by  
28 his or her state's medical commission or equivalent and his or her  
29 supervising physician, an advanced registered nurse practitioner  
30 licensed to prescribe controlled substances, or a veterinarian  
31 licensed to practice veterinary medicine in any state of the United  
32 States.

33 (nn) "Prescription" means an order for controlled substances  
34 issued by a practitioner duly authorized by law or rule in the state  
35 of Washington to prescribe controlled substances within the scope of  
36 his or her professional practice for a legitimate medical purpose.

37 (oo) "Production" includes the manufacturing, planting,  
38 cultivating, growing, or harvesting of a controlled substance.

39 (pp) "Qualifying patient" has the meaning provided in RCW  
40 69.51A.010.



1 (qq) "Recognition card" has the meaning provided in RCW  
2 69.51A.010.

3 (rr) "Retail outlet" means a location licensed by the board for  
4 the retail sale of cannabis concentrates, useable cannabis, and  
5 cannabis-infused products.

6 (ss) "Secretary" means the secretary of health or the secretary's  
7 designee.

8 (tt) "State," unless the context otherwise requires, means a  
9 state of the United States, the District of Columbia, the  
10 Commonwealth of Puerto Rico, or a territory or insular possession  
11 subject to the jurisdiction of the United States.

12 (uu) "THC concentration" means percent of (~~delta-9~~)  
13 tetrahydrocannabinol content (~~per dry weight~~) of any part of the  
14 plant *Cannabis*, or per volume or weight of cannabis product, or the  
15 combined percent of (~~delta-9~~) tetrahydrocannabinol and  
16 tetrahydrocannabinolic acid in any part of the plant *Cannabis*  
17 regardless of moisture content.

18 (vv) "Ultimate user" means an individual who lawfully possesses a  
19 controlled substance for the individual's own use or for the use of a  
20 member of the individual's household or for administering to an  
21 animal owned by the individual or by a member of the individual's  
22 household.

23 (ww) "Useable cannabis" means dried cannabis flowers. The term  
24 "useable cannabis" does not include either cannabis-infused products  
25 or cannabis concentrates.

26 (xx) "Youth access" means the level of interest persons under the  
27 age of twenty-one may have in a vapor product, as well as the degree  
28 to which the product is available or appealing to such persons, and  
29 the likelihood of initiation, use, or addiction by adolescents and  
30 young adults.

31 (yy) "Package" means a container that has a single unit or group  
32 of units.

33 (zz) "Unit" means an individual consumable item within a package  
34 of one or more consumable items in solid, liquid, gas, or any form  
35 intended for human consumption.

36 **Sec. 3.** RCW 69.50.326 and 2022 c 16 s 55 are each amended to  
37 read as follows:

38 (1) Licensed cannabis producers and licensed cannabis processors  
39 may use a CBD product as an additive for the purpose of enhancing the

1 cannabidiol concentration of any product authorized for production,  
2 processing, and sale under this chapter. Except as otherwise provided  
3 in subsection (2) of this section, such CBD product additives must be  
4 lawfully produced by, or purchased from, a producer or processor  
5 licensed under this chapter.

6 (2) Subject to the requirements set forth in (a) (~~and (b)~~)  
7 through (c) of this subsection, and for the purpose of enhancing the  
8 cannabidiol concentration of any product authorized for production,  
9 processing, or sale under this chapter, licensed cannabis producers  
10 and licensed cannabis processors may use a CBD product obtained from  
11 a source not licensed under this chapter, provided the CBD product:

12 (a) (~~Has a THC level of 0.3 percent or less on a dry weight~~  
13 ~~basis; and~~

14 ~~(b)~~) Is not cannabis, or a cannabis product, as defined in this  
15 chapter;

16 (b) Is not a synthetic cannabinoid; and

17 (c) Has been tested for contaminants and toxins by a testing  
18 laboratory accredited under this chapter and in accordance with  
19 testing standards established under this chapter and the applicable  
20 administrative rules.

21 (3) Subject to the requirements of this subsection (3), the board  
22 may enact rules necessary to implement the requirements of this  
23 section. Such rule making is limited to regulations pertaining to  
24 laboratory testing and product safety standards for those cannabidiol  
25 products used by licensed producers and processors in the manufacture  
26 of cannabis products marketed by licensed retailers under this  
27 chapter. The purpose of such rule making must be to ensure the safety  
28 and purity of cannabidiol products used by cannabis producers and  
29 processors licensed under this chapter and incorporated into products  
30 sold by licensed recreational cannabis retailers. This rule-making  
31 authority does not include the authority to enact rules regarding  
32 either the production or processing practices of the industrial hemp  
33 industry or any cannabidiol products that are sold or marketed  
34 outside of the regulatory framework established under this chapter.

35 **Sec. 4.** RCW 69.50.346 and 2022 c 16 s 66 are each amended to  
36 read as follows:

37 (1) The label on a cannabis product (~~container~~) package,  
38 including cannabis concentrates, useable cannabis, or cannabis-  
39 infused products, sold at retail must include:

- 1 (a) The business or trade name and Washington state unified  
2 business identifier number of the cannabis producer and processor;
- 3 (b) The lot numbers of the product;
- 4 (c) The THC concentration and CBD concentration of the product;
- 5 (d) Medically and scientifically accurate and reliable  
6 information about the health and safety risks posed by cannabis use;
- 7 (e) Language required by RCW 69.04.480; and
- 8 (f) A disclaimer, subject to the following conditions:
- 9 (i) Where there is one statement made under subsection (2) of  
10 this section, or as described in subsection (5)(b) of this section,  
11 the disclaimer must state "This statement has not been evaluated by  
12 the State of Washington. This product is not intended to diagnose,  
13 treat, cure, or prevent any disease."; and
- 14 (ii) Where there is more than one statement made under subsection  
15 (2) of this section, or as described in subsection (5)(b) of this  
16 section, the disclaimer must state "These statements have not been  
17 evaluated by the State of Washington. This product is not intended to  
18 diagnose, treat, cure, or prevent any disease."
- 19 (2)(a) For cannabis products that have been identified by the  
20 department in rules adopted under RCW 69.50.375(4) in chapter 246-70  
21 WAC as being a compliant cannabis product, the product label and  
22 labeling may include a structure or function claim describing the  
23 intended role of a product to maintain the structure or any function  
24 of the body, or characterize the documented mechanism by which the  
25 product acts to maintain such structure or function, provided that  
26 the claim is truthful and not misleading.
- 27 (b) A statement made under (a) of this subsection may not claim  
28 to diagnose, mitigate, treat, cure, or prevent any disease.
- 29 (3) The labels and labeling may not be:
- 30 (a) False or misleading; or
- 31 (b) Especially appealing to children.
- 32 (4) The label is not required to include the business or trade  
33 name or Washington state unified business identifier number of, or  
34 any information about, the cannabis retailer selling the cannabis  
35 product.
- 36 (5) A cannabis product is not in violation of any Washington  
37 state law or rule of the board solely because its label or labeling  
38 contains:
- 39 (a) Directions or recommended conditions of use; or

1 (b) A warning describing the psychoactive effects of the cannabis  
2 product, provided that the warning is truthful and not misleading.

3 (6) This section does not create any civil liability on the part  
4 of the state, the board, any other state agency, officer, employee,  
5 or agent based on a cannabis licensee's description of a structure or  
6 function claim or the product's intended role under subsection (2) of  
7 this section.

8 (7) Nothing in this section shall apply to a drug, as defined in  
9 RCW 69.50.101, or a pharmaceutical product approved by the United  
10 States food and drug administration.

11 NEW SECTION. **Sec. 5.** A new section is added to chapter 69.50  
12 RCW to read as follows:

13 (1) Except as otherwise provided in this chapter, no person may  
14 manufacture, sell, or distribute cannabis, cannabis concentrates,  
15 useable cannabis, or cannabis-infused products, or any cannabis  
16 products without a valid license issued by the board or commission.

17 (2) Any person performing any act requiring a license under this  
18 title, without having in force an appropriate and valid license  
19 issued to the person, is in violation of this chapter.

20 (3) The producing, processing, manufacturing, or sale of any  
21 synthetically derived, or completely synthetic, cannabinoid is  
22 prohibited, except for products approved by the United States food  
23 and drug administration.

24 NEW SECTION. **Sec. 6.** Nothing in this act shall be construed to  
25 require any agency to purchase a liquid chromatography-mass  
26 spectrometry instrument.

27 NEW SECTION. **Sec. 7.** If any provision of this act or its  
28 application to any person or circumstance is held invalid, the  
29 remainder of the act or the application of the provision to other  
30 persons or circumstances is not affected."

31 Correct the title.

EFFECT: (1) Adds a definition of the term "hemp consumable" to  
hemp statutes. Defines the term as a product that is sold or provided  
to another person, that is: (a) Made of hemp; (b) not a cannabis  
product; and (c) intended to be consumed or absorbed inside the body  
by any means, including inhalation, ingestion, or insertion.

(2) Modifies the proposed change to the existing definition of the term "cannabis products" in the Uniform Controlled Substances Act (UCSA), so the definition would include any product intended to be consumed or absorbed inside the body by any means including inhalation, ingestion, or insertion, with any detectable amount of THC (instead of with any amount of THC).

(3) Also excludes products that are approved by the United States Food and Drug Administration from the definition of the term "cannabis products" in the UCSA.

(4) Removes the proposed new definition of "tetrahydrocannabinol" or "THC," and the proposed change to the existing definition of "isomer" in the UCSA.

(5) Prohibits synthetic cannabinoids from being used as additives in cannabis products, instead of requiring the label on a cannabis product package to include the amount of any synthetically derived CBD in a product.

(6) Prohibits the production, processing, manufacturing, or sale of any cannabinoid that is synthetically derived or completely synthetic, except for products approved by the United States Food and Drug Administration.

(7) Adds a severability clause.

--- END ---